FDA approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - March 19, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s MabThera (rituximab) for a rare autoimmune disease
Roche today announced that the European Commission has approved MabThera ® (rituximab) for the treatment of adults with moderate to severe pemphigus vulgaris (PV), a rare condition characterised by progressive painful blistering of the skin and/or mucous membranes. (Source: Roche Media News)
Source: Roche Media News - March 15, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Roche today announced that the European Commission has approved Hemlibra ® (emicizumab) for routine prophylaxis of bleeding episodes in people with severe haemophilia A (congenital factor VIII deficiency, FVIII (Source: Roche Media News)
Source: Roche Media News - March 14, 2019 Category: Pharmaceuticals Source Type: news

Roche ’s VENTANA PD-L1 (SP142) Assay approved as first companion diagnostic to identify triple-negative breast cancer patients eligible for treatment with Tecentriq in combination with Abraxane
Roche today announced US Food and Drug Administration approval of the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying triple-negative breast cancer (TNBC) patients eligible for treatment with the Roche cancer immunotherapy Tecentriq ®(atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]). (Source: Roche Media News)
Source: Roche Media News - March 11, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Roche ’s Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose tumours express PD-L1, as determined by an FDA-approved test. (Source: Roche Media News)
Source: Roche Media News - March 11, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - March 8, 2019 Category: Pharmaceuticals Source Type: news

Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc. (NASDAQ: ONCE) at a price of US$ 114.50 per share. (Source: Roche Media News)
Source: Roche Media News - March 7, 2019 Category: Pharmaceuticals Source Type: news

Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Roche today announced the submission of a supplemental New Drug Application to the US Food and Drug Administration (FDA) for Venclexta ® (venetoclax) in combination with Gazyva® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions. (Source: Roche Media News)
Source: Roche Media News - March 7, 2019 Category: Pharmaceuticals Source Type: news

Roche Annual General Meeting 2019
Roche today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). The 840 attending shareholders, representing 86.73% of the total of 160,000,000 shares, approved the Management Report, the Financial Statements and the Consolidated Financial Statements for 2018. (Source: Roche Media News)
Source: Roche Media News - March 5, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta ™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metast atic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease. (Source: Roche Media News)
Source: Roche Media News - February 28, 2019 Category: Pharmaceuticals Source Type: news

Roche enters into definitive merger agreement to acquire Spark Therapeutics
Roche and Spark Therapeutics, Inc. today announced that they have entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of US$ 114.50 per share in an all-cash transaction. (Source: Roche Media News)
Source: Roche Media News - February 25, 2019 Category: Pharmaceuticals Source Type: news

FDA grants Priority Review to Roche ’s personalised medicine entrectinib
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and paediatric patients with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced or metastatic solid tumours who have either progressed following prior therapies or as an initial therapy when there are no acceptable standard therapies, and for the treatment of people with metastatic, ROS1-positive non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - February 19, 2019 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s polatuzumab vedotin in previously treated aggressive lymphoma
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company ’s Biologics License Application (BLA) and granted Priority Review for polatuzumab vedotin in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). (Source: Roche Media News)
Source: Roche Media News - February 19, 2019 Category: Pharmaceuticals Source Type: news

Roche joins the World Federation of Hemophilia Humanitarian Aid Program
Roche today announced that it has joined the World Federation of Hemophilia (WFH) Humanitarian Aid Program, a landmark initiative leading the effort to change the lack of access to care and treatment for people with inherited bleeding disorders in developing countries. (Source: Roche Media News)
Source: Roche Media News - February 6, 2019 Category: Pharmaceuticals Source Type: news

Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced completing the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant (before surgery) treatment. (Source: Roche Media News)
Source: Roche Media News - February 5, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Roche today announced that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Hemlibra ®(emicizumab) for routine prophylaxis of bleeding episodes in adults and children with severe haemophilia A (congenital factor VIII deficiency, FVIII (Source: Roche Media News)
Source: Roche Media News - February 1, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab), in combination with Avastin® (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) . (Source: Roche Media News)
Source: Roche Media News - February 1, 2019 Category: Pharmaceuticals Source Type: news

Roche reports very strong results in 2018
Group sales increase 7% at constant exchange rates and in Swiss francs (Source: Roche Media News)
Source: Roche Media News - January 31, 2019 Category: Pharmaceuticals Source Type: news

Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer ’s disease (AD) - other company programmes in AD continue
- Roche today announced the decision to discontinue CREAD I and CREAD 2 (BN29552 and BN29553) Phase III studies of the investigational anti-beta-amyloid molecule crenezumab in people with early (prodromal to mild) sporadic Alzheimer ’s disease (AD). The decision was based on the results of a pre-planned interim analysis assessing the safety and efficacy of crenezumab conducted by the Independent Data Monitoring Committee, which indicated that crenezumab was unlikely to meet the primary endpoint of change from baseline in Clin ical Dementia Rating-Sum of Boxes (CDR-SB) Score. No safety signals for crenezumab were obse...
Source: Roche Media News - January 30, 2019 Category: Pharmaceuticals Source Type: news

FDA accepts Roche ’s supplemental biologics license application for Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) for Tecentriq® (atezolizumab) in combination with Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumour aberrations. (Source: Roche Media News)
Source: Roche Media News - January 17, 2019 Category: Pharmaceuticals Source Type: news

PRIME designation granted by European Medicines Agency for Roche ’s risdiplam for treatment of spinal muscular atrophy (SMA)
Roche today announced that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation for the company ’s investigational oral medicine risdiplam (RG7916) for the treatment of people with SMA. (Source: Roche Media News)
Source: Roche Media News - December 17, 2018 Category: Pharmaceuticals Source Type: news

New member proposed for election to Roche Board of Directors
Roche today announced that at its December meeting the Board of Directors (BoD) of Roche Holding Ltd decided on first proposals for approval by the Annual General Meeting (AGM), scheduled for 5 March 2019. (Source: Roche Media News)
Source: Roche Media News - December 10, 2018 Category: Pharmaceuticals Source Type: news

Changes to the Roche Corporate Executive Committee
Roche today announced that Daniel O ’Day, CEO Roche Pharmaceuticals and member of the Corporate Executive Committee, will be stepping down from his role as of 31 December 2018. (Source: Roche Media News)
Source: Roche Media News - December 10, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche today announced that the US Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumour aberrations. (Source: Roche Media News)
Source: Roche Media News - December 7, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p (Source: Roche Media News)
Source: Roche Media News - December 5, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy), for the initial (first-line) treatment of people with extensive-stage small cell lung cancer (ES - SCLC). (Source: Roche Media News)
Source: Roche Media News - December 5, 2018 Category: Pharmaceuticals Source Type: news

New Venclexta/Venclyxto data demonstrate deep responses in two of the most common types of leukaemia
Roche today announced new data from the Venclexta ®/Venclyxto® (venetoclax) clinical development programme, including longer-term results from the phase III MURANO study in people with previously treated chronic lymphocytic leukaemia (CLL) and updated data from two phase Ib/II studies in people with previously untreated acute myeloid leukaemia (A ML) ineligible for intensive chemotherapy due to coexisting medical conditions. (Source: Roche Media News)
Source: Roche Media News - December 4, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Hemlibra provided sustained bleed control in the largest pivotal study to date of children with haemophilia A with factor VIII inhibitors
Roche today announced data from the primary analysis of the phase III HAVEN 2 study evaluating Hemlibra ® (emicizumab) prophylaxis in children younger than 12 years of age with haemophilia A with factor VIII inhibitors, including longer follow-up for once-weekly dosing and new data for less frequent dosing schedules (every two weeks or every four weeks). (Source: Roche Media News)
Source: Roche Media News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Longer-term follow-up data demonstrate sustained benefit of polatuzumab vedotin-based treatment in relapsed or refractory diffuse large B-cell lymphoma
Roche today announced longer-term data from the phase Ib/II GO29365 study showing that polatuzumab vedotin, an investigational anti-CD79b antibody drug conjugate (ADC), in combination with MabThera ®/Rituxan® (rituximab) plus bendamustine (BR), demonstrated a median overall survival (OS) of over one year compared to the BR arm (12.4 vs. 4.7 months, HR 0.42; 95% CI 0.24, 0.75), in people with R/R DLBCL not eligible for a haematopoietic stem cell transplant. OS was an exploratory endpoint. (Source: Roche Media News)
Source: Roche Media News - December 3, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy
Roche today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Venclexta ® (venetoclax), in combination with a hypomethylating agent (azacitidine or decitabine), or low dose cytarabine (LDAC), for the treatment of people with newly-diagnosed acute myeloid leukaemia (AML), who are age 75 years or older, or for those ineligible for intensive induction chemotherapy due to coexisting medical conditions. (Source: Roche Media News)
Source: Roche Media News - November 21, 2018 Category: Pharmaceuticals Source Type: news

FDA grants priority review to Roche ’s Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
Roche today announced the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast can cer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing. (Source: Roche Media News)
Source: Roche Media News - November 13, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new data from its industry-leading haematology portfolio at the American Society of Hematology 2018 Annual Meeting
Roche today announced that new data for its approved and investigational medicines across a range of blood diseases, and including several first-in-class medicines, will be presented at the 60th American Society of Hematology (ASH) Annual Meeting from 1-4 December, 2018. (Source: Roche Media News)
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Phase III data showed that Venclexta/Venclyxto plus Gazyva/Gazyvaro reduced the risk of disease worsening or death in people with previously untreated chronic lymphocytic leukaemia with co-morbidities
Roche announced today that the randomised phase III CLL14 study, which evaluated fixed-duration Venclexta ®/Venclyxto® (venetoclax) in combination with Gazyva®/Gazyvaro® (obinutuzumab) in people with previously untreated chronic lymphocytic leukaemia (CLL) and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death (PFS; as assessed by investigator) compared to standard-of-care Gazyva/Gazyvaro plus chlorambucil. The results showed that no new safety signals or increase in known toxicities of Venclexta/Venclyxto or Ga...
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Roche today announced that the European Commission has approved Venclyxto ® (venetoclax) in combination with MabThera® (rituximab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy. (Source: Roche Media News)
Source: Roche Media News - November 1, 2018 Category: Pharmaceuticals Source Type: news

New STAIRWAY study data shows potential for extended durability with Roche ’s faricimab in neovascular age-related macular degeneration (nAMD)
Roche today announced positive results from the phase II STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of neovascular ( “wet”) age-related macular degeneration (nAMD), a leading cause of blindness globally in people aged 60 and over. (Source: Roche Media News)
Source: Roche Media News - October 29, 2018 Category: Pharmaceuticals Source Type: news

Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza
Roche today announced that the US Food and Drug Administration (FDA) has approved Xofluza ™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older. (Source: Roche Media News)
Source: Roche Media News - October 24, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Alecensa (alectinib) significantly reduced the risk of disease worsening or death as a first-line treatment in Asian patients with ALK-positive advanced or metastatic non-small cell lung cancer
Roche will today announce results from the phase III ALESIA study, showing that Alecensa ® (alectinib) met its primary endpoint of investigator-assessed (INV) progression-free survival (PFS). (Source: Roche Media News)
Source: Roche Media News - October 22, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
Roche today announced positive results from the Phase III IMpower130 study of Tecentriq ® (atezolizumab) plus chemotherapy (carboplatin and Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of people with previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC). The analysis showed that Tecentriq plus chemotherapy help ed people live significantly longer compared to chemotherapy alone (median overall survival [OS] =18.6 versus 13.9 months; hazard ratio [HR]=0.79; 95% CI: 0.64–0.98; p=0.033) in the intention-to-treat wild-type (ITT-WT) populatio...
Source: Roche Media News - October 22, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s investigational personalised medicine entrectinib shrank tumours in people with NTRK fusion-positive solid tumours
Roche today announced results from an integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials that showed the investigational personalised medicine entrectinib shrank tumours (objective response rate; ORR) in more than half (57.4%) of people with neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive solid tumours. (Source: Roche Media News)
Source: Roche Media News - October 21, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Roche today announced positive results from the Phase III IMpassion130 study of Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). (Source: Roche Media News)
Source: Roche Media News - October 20, 2018 Category: Pharmaceuticals Source Type: news

Roche reports very strong growth in the first nine months of 2018
Group sales increase 7% at constant exchange rates and in Swiss francs. Pharmaceuticals Division sales up 7%, driven mainly by Ocrevus, Perjeta, Alecensa and Tecentriq. Diagnostics Division sales grow 6%, primarily due to demand for immunodiagnostic solutions. (Source: Roche Media News)
Source: Roche Media News - October 17, 2018 Category: Pharmaceuticals Source Type: news

Roche launches NGS AVENIO Tumor Tissue Analysis Kits for oncology research
Roche today announced the global commercial launch of three new next-generation sequencing (NGS) AVENIO Tumor Tissue Analysis Kits – the AVENIO Tumor Tissue Targeted Kit, Expanded Kit and Surveillance Kit. (Source: Roche Media News)
Source: Roche Media News - October 15, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. (Source: Roche Media News)
Source: Roche Media News - October 15, 2018 Category: Pharmaceuticals Source Type: news

OCREVUS (ocrelizumab) data show early initiation of treatment reduces disability progression over five years in relapsing and primary progressive multiple sclerosis
Roche announced today that new OCREVUS ® (ocrelizumab) data will be presented at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) from 10 October to 12 October in Berlin, Germany. (Source: Roche Media News)
Source: Roche Media News - October 10, 2018 Category: Pharmaceuticals Source Type: news

Roche to present new positive data from its broad cancer immunotherapy programme and across a wide range of cancers at the European Society for Medical Oncology (ESMO) 2018 Congress
Roche today announced that new results from a number of studies across its industry leading oncology portfolio of approved and investigational medicines will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress, taking place from 19-23 October, in Munich, Germany. (Source: Roche Media News)
Source: Roche Media News - October 9, 2018 Category: Pharmaceuticals Source Type: news

FDA approves Roche ’s Hemlibra for haemophilia A without factor VIII inhibitors
Roche announced today that the US Food and Drug Administration (FDA) has approved Hemlibra ® (emicizumab-kxwh) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with haemophilia A without factor VIII inhibitors. (Source: Roche Media News)
Source: Roche Media News - October 4, 2018 Category: Pharmaceuticals Source Type: news

Positive phase III results for baloxavir marboxil in people at high risk of complications from influenza to be presented at IDWeek 2018
Roche today announced that the phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo (median time of 73.2 hours versus 102.3 hours; p (Source: Roche Media News)
Source: Roche Media News - October 4, 2018 Category: Pharmaceuticals Source Type: news

Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
Roche today announced interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam (RG7916) in SMA. (Source: Roche Media News)
Source: Roche Media News - October 3, 2018 Category: Pharmaceuticals Source Type: news

Roche to present five-year OCREVUS (ocrelizumab) efficacy and safety data in relapsing and primary progressive multiple sclerosis (MS) at ECTRIMS
Roche announced today that new data on OCREVUS ® (ocrelizumab) in people with relapsing and primary progressive forms of MS will be presented during the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting in Berlin, Germany, 10 to 12 October. (Source: Roche Media News)
Source: Roche Media News - October 2, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with chemotherapy helped people live significantly longer as an initial treatment for people with extensive-stage small cell lung cancer
Roche today announced positive results from the Phase III IMpower133 study of Tecentriq ® (atezolizumab) plus carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of people with previously-untreated extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - September 25, 2018 Category: Pharmaceuticals Source Type: news